Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma

Lenvatinib was recently approved as a novel first-line molecular targeted agent (MTA) for treating hepatocellular carcinoma (HCC). The importance of relative dose intensity (RDI) has been shown in the treatment of various types of cancers. However, RDI may not accurately reflect the treatment intens...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yuji Eso, Shigeharu Nakano, Masako Mishima, Soichi Arasawa, Eriko Iguchi, Fumiyasu Nakamura, Haruhiko Takeda, Atsushi Takai, Ken Takahashi, Kojiro Taura, Hiroshi Seno
Format: Artigo
Idioma:Inglês
Publicat: MDPI AG 2019-12-01
Col·lecció:Cancers
Matèries:
albi grade
body surface area
dose intensity
hepatocellular carcinoma
lenvatinib
molecular-targeted therapy
relative dose intensity
Accés en línia:https://www.mdpi.com/2072-6694/12/1/49
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars